Source: DGNews  |  Posted 8 years ago

By Bonnie Darves

BARCELONA, SPAIN -- October 28, 2003 -- A new Phase III study provides further evidence that etanercept (Enbrel) is both effective and safe as first-line monotherapy for the treatment of moderate to severe psoriasis, researchers announced on October 18th at the European Academy of Dermatology and Venereology Congress.

Reporting on results from the first 24 weeks of the one-year study, Alice Gottlieb, MD, PhD, director of the Clinical Research Center at Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States, said patients taking etanercept in doses of either 25 mg or 50 mg subcutaneously up to twice weekly experienced not only significant symptom reduction but also "dramatic improvement in all quality of life indices used